Home > Pulmonology > ATS 2022 > Type 2 asthma managed by dupilumab, despite atopic comorbidities

Type 2 asthma managed by dupilumab, despite atopic comorbidities

Presented By
Prof. Theresa Guilbert, University of Cincinnati, OH, USA
ATS 2022
Phase 3, Liberty Asthma VOYAGE
The phase 3 Liberty Asthma VOYAGE trial reported that dupilumab reduced severe asthma exacerbation rates and also improved overall lung function in children with moderate-to-severe asthma, independent of the presence of atopic comorbidities, including chronic rhinosinusitis, nasal polyps, or eosinophilic oesophagitis. A new post hoc analysis of the Evaluation of Dupilumab in Children with Uncontrolled Asthma trial (Liberty Asthma VOYAGE, NCT02948959) which was presented by Prof. Theresa Guilbert (University of Cincinnati, OH, USA) took a look at the effect of dupilumab, a monoclonal antibody that blocks 2 primary drivers of type 2 inflammation (IL-4 and IL-13), on comorbid atopic disorders and type 2 inflammation in that cohort. The main Liberty Asthma VOYAGE trail evaluated the efficacy of dupilumab 100/200 mg every 2 weeks compar...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on